2019 Commercially Supported Symposia
The following Commercially Supported Symposia (CSS) held during the AAPM 35th Annual Meeting & Preconferences March 7-9, 2019 offered meeting attendees an opportunity to expand their pain management knowledge and gain insight into the important topics and issues facing today’s pain specialists.
Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention
Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. During this PeerView Live lunch symposium, after briefly reviewing how migraine can be identified in clinical practice, experts in the management of this neurologic disorder will discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice.
- Apply established screening tools and criteria for migraine diagnosis in clinical practice.
- Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine.
- Cite updated evidence on available and emerging therapies for the prevention of migraine.
- Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.
This activity is supported by an educational grant from Lilly.
The Long Lasting Impact of a Short Conversation About Opioid Overdose Risks
Despite mounting concern and efforts to address opioid overdose in the United States, death rates involving prescription opioids have not abated. This statistic highlights missed opportunities for clinicians to intervene to help save lives. Numerous government agencies and professional organizations recommend that clinicians co-prescribe take-home naloxone with opioids for at-risk patients as a precaution to help prevent opioid overdose deaths. While it is necessary to first identify patients at risk of an opioid overdose, just as important is engaging in conversations that can help save patients’ lives. The faculty will model a brief and impactful conversation with patients and care partners in a way that facilitates patient acceptance to take-home naloxone being part of their chronic pain treatment plan.
After attending this symposium, participants should be better able to:
- Identify patients at risk for an opioid overdose.
- Facilitate brief and impactful conversations with patients and care partners around risk of opioid overdose and the need for take-home naloxone.
- Implement strategies to incorporate communication about opioid overdose and take-home naloxone into clinical protocols when prescribing opioids.
Activity sponsored by kaleo, Inc.
Opioid Therapy Insights: A Holistic Approach to Managing Patients
In this interactive, industry-sponsored presentation, we will discuss when to consider an abuse-deterrent opioid for chronic pain. We will also explore treatment options for opioid-induced constipation in adult patients with chronic non-cancer pain.
Activity sponsored by Daiichi Sankyo, Inc. & Inspirion Delivery Sciences.
Alternative Options to the Management of Chronic Pain
To review and discuss the unique pharmacologic properties, clinical efficacy, and use of an alternative option for the management of chronic pain.
Activity sponsored by BioDelivery Sciences International, Inc.
Exploring the Burden, Diagnosis and Treatment of Migraine: What Pain Specialists Need to Know
This presentation discussed migraine diagnosis, classification, and treatment as well as migraine-associated patient burden.
Activity sponsored by Novartis and Amgen.